A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma
Science Immunology · 2024
DOI: 10.1126/sciimmunol.adp3720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Olivier Demaria und 33 weiteren Autor:innen. Beteiligte Einrichtung: Innate Pharma Research Laboratories, Innate Pharma, Marseille, France. Hauptthemen laut MEDLINE: Killer Cells, Natural, Interleukin-2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: European Research Council.
Abstract (Originalsprache)
NK cells offer a promising alternative to T cell therapies in cancer. We evaluated IPH6501, a clinical-stage, tetraspecific NK cell engager (NKCE) armed with a non-alpha IL-2 variant (IL-2v), which targets CD20 and was developed for treating B cell non-Hodgkin lymphoma (B-NHL). CD20-NKCE-IL2v boosts NK cell proliferation and cytotoxicity, showing activity against a range of B-NHL cell lines, including those with low CD20 density. Whereas it presented reduced toxicities compared with those commonly associated with T cell therapies, CD20-NKCE-IL2v showed greater killing efficacy over a T cell engager targeting CD20 in in vitro preclinical models. CD20-NKCE-IL2v also increased the cell surface expression of NK cell–activating receptors, leading to activity against CD20-negative tumor cells. In vivo studies in nonhuman primates and tumor mouse models further validated its efficacy and revealed that CD20-NKCE-IL2v induces peripheral NK cell homing at the tumor site. CD20-NKCE-IL2v emerges as a potential alternative in the treatment landscape of B-NHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Innate Pharma Research Laboratories, Innate Pharma, Marseille, France.
- Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
- APHM, Hôpital de la Timone, Marseille-Immunopôle Profiling Platform, Marseille, France.
- Paris-Saclay Cancer Cluster, Le Kremlin-Bicêtre, France.
- Université Paris-Saclay, Gustave Roussy, INSERM, Prédicteurs moléculaires et nouvelles cibles en oncologie, 94800, Villejuif, France.
ORCID-Profile: Olivier Demaria, Guillaume Habif, Laurent Gauthier, Laura Chiossone, Constance Vagne, Lucas Rebuffet, Rachel Courtois, Caroline Denis, Aurélie Maguer, Jean-Baptiste Vallier, Eric Vivier
Förderung
- European Research Council
Zitieren
APA
Demaria, O., Habif, G., Vetizou, M., Gauthier, L., Remark, R., Chiossone, L., Vagne, C., Rebuffet, L., Courtois, R., Denis, C., Le Floch, F., Muller, M., Girard-Madoux, M., Augier, S., Lopez, J., Carrette, B., Maguer, A., Vallier, J. B., Grondin, G., …, & Vivier, E. (2024). A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma. Science Immunology. https://doi.org/10.1126/sciimmunol.adp3720
Vancouver
Demaria O, Habif G, Vetizou M, Gauthier L, Remark R, Chiossone L, et al. A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma. Science Immunology. 2024. doi:10.1126/sciimmunol.adp3720
BibTeX
@article{Demaria2024,
author = {Demaria, Olivier and Habif, Guillaume and Vetizou, Marie and Gauthier, Laurent and Remark, Romain and Chiossone, Laura and Vagne, Constance and Rebuffet, Lucas and Courtois, Rachel and Denis, Caroline and Le Floch, François and Muller, Marianna and Girard-Madoux, Mathilde and Augier, Séverine and Lopez, Julie and Carrette, Barbara and Maguer, Aurélie and Vallier, Jean-Baptiste and Grondin, Gwendoline and Baron, William and Galluso, Justine and Yessaad, Nadia and Giordano, Marilyn and Simon, Léa and Chanuc, Fabien and Alvarez, Audrey Blanchard and Perrot, Ivan and Bonnafous, Cécile and Represa, Agnès and Rossi, Benjamin and Morel, Ariane and Morel, Yannis and Paturel, Carine and Vivier, Eric},
title = {A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma},
journal = {Science Immunology},
year = {2024},
doi = {10.1126/sciimmunol.adp3720}
}
EUVIMED